
Minutes of the Meeting No. 11/2023 held on December 8, 2023**Joint meeting of the IOCB Board and Supervisory Board**

Present (in arrival order, omitting titles):

Supervisory Board: Martin Bilej (chair), Zlatko Janeba (vice-chair), Libor Grubhoffer, Matěj Kliman, Jiří Krechl, Josef Lazar, Michal Strouhal

IOCB Board: Pavel Jungwirth (chair), Michal Hocek (vice-chair), Radek Cibulka, Jan Černý, Martin Dračínský, Pavel Majer, Pavlína Maloy Řezáčová, Petr Slavíček, Kvido Stříšovský

Guests: Jan Konvalinka (IOCB Director), Jiří Polman (strategic advisory), Jiří Cairola (head of the Technical-Economic Administration), Milan Prášil (i&i Prague)

Secretary: Irena Valterová

Agenda:

1. The program of the meeting was approved unanimously. The per-rollam voting No. 4/2023 was verified (intention of establishing IOCB Boston and lease of lab space in Riverside Technology Center, Cambridge, USA).
2. The Director has informed both Boards about the progress in leasing contract with Rivertech Associates II, LLC. The lab space is approximately 8,570 rentable square feet ("RSF") representing a portion of the 1st floor of the building and 50 RSF on the garage level for an acid neutralization room for a total Premises of 8,620 RSF. The duration of the contract will be 5 years. The laboratories will be used for the research group of David Sabatini who is employed at IOCB since October 2023. IOCB Boston has been registered as non-profit (charitable) organization and has a US employer identification number (EIN).
3. Pavel Jungwirth informed about efforts to improve communication within IOCB. The electronic bulletin "The Bond", published earlier at IOCB and now inactive for several years, will be re-introduced. A more regular flow of information should go from the management to employees.
4. Milan Prášil informed about current developments in IOCB Tech, i&i Prague and i&i Bio. IOCB Tech develops 16 commercialization projects, the most promising ones being cGAS-STING antagonist for potential use as an anti-inflammatory treatment, CDK9-kinase

inhibitor for oncology and the project CHEESE (chemical embedded search engine) of an AI based tool for medicinal chemistry. The IOCB Tech team also work on preparation of several new start-up companies (commercializing e.g. the project of Lipid Nanoparticles for targeted therapy, and SQM Scoring – quantum mechanics scoring for drug design). Both Boards were also informed about activities of the IOCB Tech Foundation in the area of the support of local science. In the year of 2023 the overall support via the foundation has reached 15 mil CZK.

Concerning i&i Prague, the Board members were informed about the personnel change at the position of Chairman of board of directors. Former director of i&i Prague, dr. Jaromír Zahradka resigned to Oct 31, 2023 and was replaced from Nov.1, 2023 by dr. Milan Prášil. This change was planned in order to let dr. Zahradka fully concentrate on the management and development of the i&i Bio fund and the consequent preparation of the new fund from the year 2026. M. Prášil has further commented on the latest results of both i&i Prague and i&i Bio. The last information concerned newly established non-for-profit subject of Prague-Bio. Prague Bio is a cluster aiming to involve scientific and education institutions (research-based universities) as well as partners from the commercial innovative sector. In Sep. 2023, the cluster organized a successful conference focused on technology transfer especially emphasizing biotech and life science capacity in the area of Prague. The conference is to be held again next year (September 2024).

5. Dream Chemistry Award took place at IOCB on 4.-5.12. From about 50 applications, the DCA Committee selected 5 and invited the applicants to IOCB for presentations. The level of science was very high. IOCB Tech Foundation obtained 70 application for the Martina Roeselova Memorial Grants. Ten grants were awarded to the best applicants.
6. Pavel Jungwirth informed about the changes in the law on science-research institutions. Changes significantly restrict the competence of the Board of the institution. Therefore, the IOCB Board fully supported the critical statement of Boards formulated at the Institute of Philosophy of CAS. This statement will be presented at the Academy Assembly on December 12.
7. The Director informed about increasing psychological and other problems among PhD students. Students will be asked to fill in an anonymous questionnaire inquiring about their well-being. Based on the result, the IOCB management will then discuss the issue internally and with the corresponding universities.
8. The IOCB Board discussed the applications for investment for 2024. The Board fully agrees with the conclusions of the Methodological Board and supports their recommendations.
9. Suggested dates of next IOCB Board meetings:

January – no meeting

February – Thursday 1.2. at 2 PM

March – Thursday 7.3. at 2 PM

April – Thursday 4.4. at 2 PM

May – Thursday 16.5. at 2 PM

June – end of the month, depending on the audit and the Supervisory Board meeting.

Minutes prepared by Irena Valterová on December 12, 2023.